Target intelligence / Profile preview

Influenza A virus Matrix protein 2 ectodomain (M2e) (M2e)

Target
M2e
Molecular classification
Viral protein, Antigen, Ion channel subunit
01

Overview

The Matrix protein 2 ectodomain (M2e) is a highly conserved 24-amino acid sequence located at the N-terminus of the Influenza A virus M2 protein (UniProt P06821). While the full M2 protein functions as a pH-gated proton channel essential for viral uncoating and assembly, the M2e region is exposed on the surface of the virion and infected cells, making it a prime target for universal influenza vaccine development. Unlike the rapidly mutating hemagglutinin and neuraminidase proteins, M2e remains remarkably stable across various influenza A subtypes, including H1N1 and H5N1. Therapeutic strategies targeting M2e include monoclonal antibodies like TCN-032 and recombinant vaccines designed to elicit a broad immune response. These interventions typically rely on Fc-mediated effector functions, such as antibody-dependent cellular cytotoxicity (ADCC) and phagocytosis, to eliminate infected host cells and reduce viral shedding. Despite its potential, M2e is poorly immunogenic during natural infection, necessitating the use of carriers or adjuvants in clinical applications. Research continues to focus on M2e to provide cross-protection against both seasonal and pandemic influenza strains.

Other names
M2 ectodomainInfluenza A M2eMatrix protein 2 extracellular domainM2e peptideM2-ectodomain epitopes
02

Mechanism of action

M2e-targeting antibodies primarily facilitate viral clearance through Fc-mediated effector functions, including antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP), while small molecule inhibitors like amantadine block the M2 proton channel activity to prevent viral genome release.

03

Biological functions

Viral uncoatingViral assemblyProton transportImmune recognition
04

Disease associations

InfectionInfluenza A
05

Safety considerations

Low natural immunogenicityRequirement for potent adjuvants or carriersPotential for limited efficacy as a standalone therapy
06

Interacting drugs

4 more in the full profile.

07

Biomarkers

Anti-M2e IgG antibody titersM2e-specific T-cell activation

Source types: Peer-reviewed publication. Sources are available to Gosset users. Log in to see them.

Beyond the preview

Go deeper on Influenza A virus Matrix protein 2 ectodomain (M2e) (M2e).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Influenza A virus Matrix protein 2 ectodomain (M2e) (M2e).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call